Clinical Trial Update: Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma [Phase 2]

View source ↗

Summary

Phase II study of 177Lu-DOTATATE in adults with progressive or high-risk meningioma is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningioma

Drugs mentioned

• 177Lu-DOTATATE (Lutetium-177 dotatate)

Snippet

Sponsor: NYU Langone Health | Conditions: Meningioma | Phase 2 | Status: ACTIVE_NOT_RECRUITING